Nortech Systems Incorporated: Q3 2023 Form 10-Q Summary
Business Context and Reporting Period
Nortech Systems is a global electronics manufacturing services provider serving the medical, industrial, and aerospace and defense markets. It provides engineering, prototyping, testing, manufacturing, supply-chain management, and post-market services from facilities in the United States, Mexico, and China. The filing covers the three and nine months ended September 30, 2023, and was filed November 14, 2023.
Financial Performance and Key Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Net sales | $33.4 million | $35.3 million | $103.3 million | $98.5 million |
| Gross profit | $5.3 million | $6.3 million | $16.3 million | $15.4 million |
| Gross margin | 15.9% | 17.9% | 15.8% | 15.6% |
| Operating income | $1.1 million | $1.9 million | $3.3 million | $3.1 million |
| Operating margin | 3.4% | 5.5% | 3.2% | 3.1% |
| Net income | $1.2 million | $1.5 million | $2.5 million | $2.4 million |
| Diluted EPS | $0.42 | $0.53 | $0.87 | $0.83 |
| Cash flow from operations | Not provided for the quarter | Not provided for the quarter | $2.2 million | $1.0 million |
Q3 sales declined 5.4% year over year, while nine-month sales increased 4.9%. Medical represented $17.8 million of Q3 sales and $59.8 million for the first nine months; industrial represented $10.5 million and $29.0 million, respectively; and aerospace and defense represented $5.1 million and $14.5 million, respectively.
Q3 gross margin declined because of lower plant utilization, product mix, and continued material and labor cost inflation. Nine-month gross margin improved modestly due primarily to higher revenue and pricing actions. General and administrative expense increased to $9.3 million for the first nine months, from $8.3 million, mainly because of higher wages and professional fees.
At September 30, 2023, cash was $0.7 million and restricted cash was $0.4 million. Total current assets were $52.6 million, compared with $54.9 million at December 31, 2022. Accounts receivable were $16.0 million, inventories were $21.5 million, and contract assets were $11.7 million.
Total liabilities were $35.3 million and shareholders’ equity was $30.7 million at September 30, 2023. Borrowings under the Bank of America line of credit were $4.6 million, down from $6.9 million at year-end, but the weighted-average interest rate increased to 8.2% from 5.2%. The $16.0 million facility expires June 15, 2026, had $7.5 million of unused borrowing-base availability, and was in compliance with applicable covenants.
Material Changes Versus the Prior Comparable Period
- Q3 sales decreased $1.9 million, or 5%, as customers worked through inventory; the prior-year quarter benefited from pricing actions taken before material-cost increases.
- Nine-month sales increased $4.8 million, or 5%, reflecting continued demand and prior pricing actions.
- Medical sales fell 13.2% in Q3 but increased 10.1% for the nine-month period. Aerospace and defense sales increased 30.8% in Q3 but declined 4.6% year to date. Industrial sales declined 3.7% in Q3 and were essentially flat year to date.
- Q3 operating income decreased $0.8 million and diluted EPS decreased $0.11, primarily due to lower sales and gross margin.
- Nine-month net income increased $0.1 million and diluted EPS increased $0.04, supported by higher revenue and a lower effective tax rate.
- Operating cash flow increased to $2.2 million from $1.0 million. Capital expenditures were $1.1 million, compared with $1.7 million in the prior-year period, while net cash used in financing activities was $2.4 million.
- Total backlog was $102.3 million, down 1% year over year but up 1% from June 30, 2023. The 90-day shipment backlog was $33.8 million, down 8% year over year.
- The company adopted the current expected credit loss standard on January 1, 2023, recording a $30 thousand after-tax reduction to retained earnings. Comparative 2022 information was not restated for the new credit-loss model.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing does not provide specific quantitative revenue, earnings, or margin guidance. Management stated that existing financing arrangements, expected operating cash flows, and cash on hand should be sufficient for working capital, capital expenditures, and debt repayments for the next twelve months.
Management noted that supply-chain conditions are normalizing, lead times are declining, and customers are returning toward pre-pandemic ordering practices. Backlog comparisons may vary because of order size, manufacturing delays, contract terms, and customer delivery schedules.
- Key risks include demand volatility, supply-chain disruption, labor shortages, competition, raw-material and energy-cost inflation, foreign-exchange volatility, facility or third-party disruptions, FDA compliance, cybersecurity events, and loss of a major customer.
- Customer concentration is material: two customers represented 36% of Q3 sales and 38% of nine-month sales. Two customers represented approximately 37% of gross accounts receivable at September 30, 2023.
- The line of credit is secured by substantially all company assets and contains financial, reporting, dividend, and capital-expenditure covenants. The company reported compliance as of September 30, 2023.
- Abilitech Medical has ceased operations. Nortech recorded a full reserve against $226 thousand of related accounts receivable and inventory.
- Nortech recognized $163 thousand of revenue from related party Marpe Technologies during the first nine months of 2023. The arrangement includes a conditional grant and a potential exclusive manufacturing right, but commercial success and recovery of service contributions are uncertain.
- All employee retention credit payments had been received by September 30, 2023; the $2.65 million receivable recorded at year-end 2022 was collected.
- The company reported no material changes to previously disclosed risk factors, no defaults on senior securities, and no material changes to internal control over financial reporting. Disclosure controls were deemed effective.
Investor Verification Checklist
- Verify whether the decline in 90-day backlog converts into lower near-term shipments and plant utilization.
- Monitor gross margin for effects from pricing, labor and material inflation, product mix, and capacity utilization.
- Assess customer concentration and the collectability of accounts receivable and contract assets.
- Track interest rates, borrowing-base availability, covenant compliance, and liquidity under the secured credit facility.
- Review the sustainability of operating cash flow after capital expenditures and lease payments.
- Evaluate progress in the medical and aerospace and defense markets, including the effect of customer inventory normalization.
- Confirm the status and financial exposure of the Marpe Technologies related-party arrangement and the reserved Abilitech balances.